In short
PTC844 is an investigational substance studied in a completed Phase 1 trial for autoimmune disorders. The trial enrolled 64 healthy participants and tested single and multiple oral doses of PTC844 against a matching placebo. The study focused on the safety and tolerability of the drug, including side effects and laboratory changes. No marketing authorisation is reported for this substance.
PTC844 is an investigational substance that has been studied in a clinical trial for autoimmune disorders. It is not an authorised medicine and no marketing authorisation has been reported. The only registered trial is a Phase 1 study completed in 64 healthy participants.
Key points
- PTC844 is an investigational drug for autoimmune disorders.
- The only registered trial is a Phase 1 study completed in 64 healthy participants.
- The trial tested single and multiple oral doses of PTC844 against a placebo.
- The primary goal was to measure safety and tolerability, including adverse events and laboratory changes.
- The study used a 45 mg oral dose of PTC844.
- No marketing authorisation has been reported for PTC844.
What is PTC844?
PTC844 is an investigational drug studied for autoimmune disorders. The therapeutic area is not possible to specify from the available registry data. The substance has no other reported names, trade names, or development codes. It is not authorised as a medicine in any country according to the available records.
How does PTC844 work?
The mechanism of action of PTC844 is not described in the available registry data. The clinical trial record does not state which molecular target PTC844 acts on or how it affects the immune system. No supplementary sources are provided to explain its mechanism.
Which conditions is PTC844 studied for?
- Autoimmune disorders — the trial record lists autoimmune disorders as the condition studied, without specifying a particular disease.
How is PTC844 given?
PTC844 was given as an oral dose in the clinical trial. The trial tested a 45 mg oral dose of PTC844. No other pharmaceutical forms or routes of administration are reported.
What do the clinical trials show?
One clinical trial of PTC844 is registered. It is a Phase 1 study that has been completed. The trial enrolled 64 healthy participants and was interventional in design.
The study was divided into two parts. Part 1 characterised the safety and tolerability of single doses of PTC844 in healthy participants. Part 2 characterised the safety and tolerability of multiple doses of PTC844 in healthy participants. The primary outcome measured the type, frequency, severity, timing, and relationship to the study intervention of any adverse events and abnormalities in clinical laboratory tests, electrocardiograms, vital signs, and physical examinations.
The trial compared PTC844 at a 45 mg oral dose against a matching placebo. Because the study was conducted in healthy participants, it did not measure how well the drug treats autoimmune disorders.
What side effects are known?
The available registry data do not report specific side effects of PTC844. The trial measured adverse events as its primary outcome, but the results are not included in the registry record.